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Summary
Background Pyoderma gangrenosum (PG) is a painful, ulcerating skin disease with
poor evidence for management. Prednisolone and ciclosporin are the most com-
monly used treatments, although not previously compared within a randomized
controlled trial (RCT).
Objectives To compare the cost-effectiveness of ciclosporin and prednisolone-
initiated treatment for patients with PG.
Methods Quality of life (QoL, EuroQoL five dimensions three level questionnaire,
EQ-5D-3L) and resource data were collected as part of the STOP GAP trial: a
multicentre, parallel-group, observer-blind RCT. Within-trial analysis used bivari-
ate regression of costs and quality-adjusted life years (QALYs), with multiple
imputation of missing data, informing a probabilistic assessment of incremental
treatment cost-effectiveness from a health service perspective.
Results In the base case analysis, when compared with prednisolone, ciclosporin
was cost-effective due to a reduction in costs [net cost: £1160; 95% confidence
interval (CI) 2991 to 672] and improvement in QoL (net QALYs: 0055; 95%
CI 0018–0093). However, this finding appears driven by a minority of patients
with large lesions (≥ 20 cm2) (net cost: £5310; 95% CI 9729 to 891; net
QALYs: 0077; 95% CI 0004–0151). The incremental cost-effectiveness of
ciclosporin for the majority of patients with smaller lesions was £23 374/QALY,
although the estimate is imprecise: the probability of being cost-effective at a
willingness-to-pay of £20 000/QALY was 43%.
Conclusions Consistent with the clinical findings of the STOP GAP trial, patients
with small lesions should receive treatment guided by the side-effect profiles of
the drugs and patient preference – neither strategy is clearly a preferred use of
National Health Service resources. However, ciclosporin-initiated treatment may
be more cost-effective for patients with large lesions.
What’s already known about this topic?
• Pyoderma gangrenosum is characterized by severe, painful skin ulcers.
• Although prednisolone has been the main systemic treatment, ciclosporin has been
used increasingly because of its perceived greater effectiveness and fewer side-
effects.
© 2017 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd
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• STOP GAP was a pragmatic randomized controlled trial comparing ciclosporin and
prednisolone: clinical effectiveness was similar, but only 50% of ulcers had healed
by 6 months on either drug and adverse events were common with both drugs.
What does this study add?
• For patients with small lesions (< 20 cm2), neither treatment is clearly more cost-
effective than the other.
• However, ciclosporin-initiated treatment may be the more cost-effective option in
patients with large (≥ 20 cm2) lesions.
• Decisions about treatment will continue to be informed primarily by patient pref-
erence, underlying comorbidities, and drug side-effect profiles (e.g. serious infec-
tions with prednisolone, hypertension and renal dysfunction with ciclosporin).
Pyoderma gangrenosum (PG) is a rare, inflammatory skin dis-
ease characterized by progressive and painful necrotizing
ulcers. Typically, PG presents as a tender erythematous nodule
or pustule, quickly progressing to a large, demarcated ulcer
with purplish, undermined edges.1 PG is associated with
underlying systemic disease, and in particular with inflamma-
tory bowel disease, arthritis and haematological malignancies.2
Additionally it may develop following incidental or iatrogenic
trauma.3–5 Compared with mortality in the general popula-
tion, PG is associated with a three fold increased risk of
death;6 its ulcers are characterized by debilitating pain and
may require narcotic analgesia.1,2,7
PG is diagnosed clinically after excluding other diagnoses
because there are no adequate diagnostic tests and histological
findings are relatively nonspecific. No national or international
guidelines address PG management, which currently includes
a range of poorly evidenced topical and systemic treatment
options including antibiotics, steroids, calcineurin inhibitors
and immunosupressants.8,9 Only one randomized controlled
trial (RCT) of treatments has previously been reported in
patients with PG: a study of 30 patients compared infliximab
against placebo and showed benefit for infliximab at 2 weeks.
However, infliximab is not a first-line treatment for this con-
dition.10
Given the absence of high-quality evidence for the manage-
ment of PG, the STOP GAP trial was designed to test whether
treatment with ciclosporin was superior to prednisolone. In
brief, STOP GAP was a multicentre, parallel-group, assessor-
blind RCT, recruiting 112 adult patients, with outcomes
assessed at baseline, 6 weeks and when the ulcer had healed
(if within 6 months).11,12 Groups were balanced at baseline.
The primary end point of velocity of healing at 6 weeks was
similar between groups [adjusted mean difference 0003 cm2
daily, 95% confidence interval (CI) 020 to 021; P = 097];
healing within 6 months was similar (ciclosporin 475%,
prednisolone 472%; P = 084). Adverse reactions were simi-
lar (ciclosporin 678%, prednisolone 660%; P = 084), but
serious adverse reactions may have been more common in the
prednisolone group (ciclosporin 3%, prednisolone 13%;
P = 0082), in particular due to five serious infections that
required hospitalization for parenteral antibiotics. Having
found no difference for a range of objective and patient-
reported outcomes, the trialists concluded that treatment deci-
sions for individual patients should be guided by the different
side-effect profiles of the two drugs and patient preference.
Economic analysis is intended to inform decision-makers
about the value-for-money of treatment alternatives in a con-
text where healthcare resources are limited and prioritization
is informed (at least in part) by the efficient use of
resources.13 An economic analysis was designed integrally
within the STOP GAP trial, following a prospective analysis
plan, to provide robust evidence of cost-effectiveness to
inform health service decision-making.
Patients and methods
A within-trial patient-level cost-effectiveness analysis was
undertaken using data from the STOP GAP trial. The analysis
was from the National Health Service (NHS) perspective; indi-
vidual patient data collected within the STOP GAP trial
included NHS treatment costs and health status, estimated as
quality-adjusted life years (QALYs). Cost-effectiveness analysis
captures the effect of treatment as changes in cost and QALYs.
Because follow-up was limited to 24 weeks, no discounting of
costs and benefits was applied. The analysis followed inten-
tion-to-treat principles, in which patients were included in the
analysis according to the treatment allocated by randomization
and irrespective of subsequent care.
Outcomes
Generic health-related quality of life (QoL) was assessed using
the EuroQol (EQ) questionnaire: a patient-completed two-
page questionnaire consisting of the EQ five dimensions three
level questionnaire (EQ-5D-3L) descriptive system and the EQ
visual analogue scale (EQ-VAS).14,15 The EQ-5D-3L includes
© 2017 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd
on behalf of British Association of Dermatologists.
British Journal of Dermatology (2017)
2 Cost-effectiveness analysis of the STOP GAP trial, J.M. Mason et al.
five questions addressing mobility, self-care, usual activities,
pain/discomfort and anxiety/depression), with each dimen-
sion assessed at three levels: no problems, some problems and
extreme problems. EQ-5D scores were converted to health sta-
tus scores using the U.K. time-trade-off value set recom-
mended by the EuroQol group,16 providing a single health-
related index including 0 (death) and 1 (perfect health),
where negative scores are possible for some health states.
Patients who died during the study were subsequently scored
0 at later scheduled follow-up visits. The EQ-VAS reports self-
rated health on a vertical VAS where 100 denotes ‘best imag-
inable health state’ and 0 denotes ‘worst imaginable health
state’. Additionally, the Dermatology Life Quality Index
(DLQI) was recorded as a disease-specific measure: DLQI asks
patients 10 questions about how their skin condition has
affected their life over the past week providing an aggregate
score of range 0–30.17 QoL measures were captured at base-
line, 8 weeks and up to 24 weeks (unless healing had
occurred).
Using the trapezoidal rule, the ‘area under the curve’
(AUC) of health status scores was calculated, providing
patient-level QALY estimates for the cost-effectiveness analy-
sis.18 Similarly, EQ-VAS and DLQI scores were integrated dis-
cretely over time. Because AUC estimates were predicted to
correlate with baseline scores (and thus potential baseline
imbalances), AUC estimates were adjusted for baseline
scores.19
Resource use and cost
Resource assessments occurred at 8 and 24 weeks (or when
healed if earlier), during mandatory clinical visits, augmented
by telephone calls with patients when clinics were missed.
Use by patients of study drugs was recorded in the trial drug
log. PG-related health service contacts were recorded during
clinic visits using patient diaries as an aide memoire.
Patient costs were initially estimated in U.K. pounds sterling
(2012) as the sum of resources used weighted by their refer-
ence costs. Study drugs were prescribed at varying doses and
durations. Using national Prescribing Cost Analysis (PCA)
data,20 average costs per unit weight of therapeutic were
determined and applied to patient drug-use records: ciclos-
porin £00242 mg1 and prednisolone £00237 mg1. Costs
for inpatient stays (in days) and outpatient visits were esti-
mated using Hospital Episodes Statistics (HES) and the
National Schedule of Reference Costs (NSRC).21,22 National
HES data were explored for inpatient episodes with a primary
diagnosis of L88 Pyoderma gangrenosum: the five most com-
mon admission codes associated with that diagnosis were
included, accounting for 83% of admissions. (HES admission
codes are similar to U.S. Diagnosis-Related Group codes).23
Per diem costs for each code were estimated from the NSRC,
and a volume-weighted average cost per admission for PG was
estimated as the cost per day. Inpatient stays were costed at
£387 per day and outpatient visits at £130 per visit. General
practitioner (GP) clinic and home visits, and practice and
district nurse visits were costed using unit costs provided by
the Personal Social Services Research Unit at the University of
Kent;24 community care contacts: GP (clinic) £43, GP (home)
£110, practice nurse £14 and district nurse £39. Patient costs
were subsequently updated to 2015 U.K. pounds sterling
using the Hospital and Community Health Services index.25
Analysis
Follow-up of patients with PG within trials is problematic and
some incompleteness of data was anticipated. Consequently, a
base case analysis was constructed where missing data were
imputed using multiple imputation. The base case analysis
included the imputed within-trial incremental cost and QALYs
gained, adjusted for trial baseline covariates. Supportive sensi-
tivity analyses included only patients with complete data, thus
exploring the impact of imputation.
The base case analysis used multiple imputation, conducted
according to good practice guidance.26,27 Multiple imputation
provides unbiased estimates of treatment effect if data are
missing at random: this assumption was explored in the data,
for example by using logistic regression for missingness of
costs and QALYs against baseline variables.28 A regression
model was used to generate multiple imputed datasets (or
‘draws’) for individual treatment groups, where missing val-
ues were predicted drawing on predictive covariates: these
included age, sex, target lesion size (< 20 cm2; ≥ 20 cm2),
presence or absence of underlying systemic disease. Outcome
measures (at each time point) and costs contributed as both
predictors and imputed variables. Each draw provided a com-
plete dataset, which reflected the distributions and correlations
between variables. Predictive mean matching was used to
enhance the plausibility and robustness of imputed values, as
normality could not be assumed. The imputation model used
fully conditional (Markov chain Monte Carlo, MCMC) meth-
ods (multiple imputation by chained equations), which are
appropriate when missing and correlated data occur in more
than one variable. Each draw was analysed independently
using bivariate regression (see below) and the estimates
obtained were pooled to generate mean and variance estimates
of costs and QALYs using Rubin’s rule – a method that cap-
tures within and between variances for imputed samples.29 To
minimize the information loss of finite imputation sampling,
50 draws were taken, resulting in a loss of efficiency relative
to infinite sampling of less than 05% in all imputed values.
The distribution of imputed and observed values was com-
pared visually and statistically to establish that imputation did
not introduce bias into subsequent estimation.
Bivariate regression using seemingly unrelated regression
equations was used to model incremental changes in costs and
QALYs. This method respects the correlation of costs and out-
comes within the data, and allows adjustment for a set of
covariates, which can be explored and which improve preci-
sion.30 Baseline QoL scores were included within all models
to allow for potential baseline imbalances.19 Joint distributions
of costs and outcomes were generated using the
© 2017 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd
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(nonparametric) bootstrap method, with replicates used to
populate a cost-effectiveness plane. Bootstrapping jointly
resamples costs and outcomes from the original data with
replacement (maintaining the sample correlation structure) to
create a new bootstrap sample from which a change in costs
and QALYs are estimated. Using bias-corrected nonparametric
bootstrapping, 5000 bootstraps were taken per model or draw
evaluated. Mean estimates are reported with 95% credible
intervals.
The incremental cost-effectiveness ratio (ICER) was esti-
mated as the difference between treatments in mean total costs
divided by the difference in mean total QALYs. Value-for-
money is determined by comparing the ICER with a threshold
value, typically the National Institute for Health and Care
Excellence threshold for U.K. studies, of £20K–30K/QALY.31
This represents the willingness-to-pay (WTP) for an additional
QALY, and lower values than the threshold could be consid-
ered cost-effective for use in the NHS. Base case assumptions
are explored using a range of supportive sensitivity analyses.
The net monetary benefit (NMB) of changing treatment
was reported as a recalculation of the ICER at a range of
thresholds of WTP for an additional QALY. The NMB suc-
cinctly describes the resource gain (or loss) when investing in
a new treatment when resources can be used elsewhere at the
same threshold. NMB estimates were used to generate cost-
effectiveness acceptability curves (CEACs). The CEAC compares
the likelihood that treatments are cost-effective as the WTP
threshold varies.30
The expected value of perfect information (EVPI) is the upper
limit of the value to a healthcare system of further research to
eliminate uncertainty.32 Findings from cost-effectiveness analy-
ses remain uncertain because of the imperfect information they
use. If a wrong adoption decision (to make a treatment avail-
able) is made this will bring with it costs in terms of health ben-
efit forgone: the NMB framework allows this expected cost of
uncertainty to be determined and guide whether further
research should be conducted to eliminate uncertainty.
Analyses and modelling were undertaken in Stata 14 SE
(StataCorp LLC; College Station, TX, U.S.A.). Reporting follows
the Consolidated Health Economic Evaluation Reporting Stan-
dards (CHEERS) statement.33
Results
Completeness of data
All 112 patients included within the trial primary analysis of
effectiveness were included in the economic analysis
(Table 1). Patients with complete EQ-5D assessments for all
periods numbered 67 in total (60%). One patient died during
the study and was subsequently scored 0 on visits that fol-
lowed for both cost and EQ-5D score and is included in the
analysis. There was a pattern of decreasing completeness as
follow-up proceeded. Resource data was complete for 67
patients (60%). When considering both utilities and resource
use, complete information was available for 55 patients
(49%). Completeness of data was similar when comparing
treatment arms. Missing values were imputed to provide a
base case analysis including all 112 patients.
Complete case estimates
Mean EQ-5D scores, resource use and cost data are reported
by treatment in Table 2. Over the 24-week follow-up period
there were no significant differences in QALYs when compar-
ing treatments. Differences in resource use comparing groups
were not statistically significant at any time point, although
there is a suggestion of greater inpatient usage by patients on
prednisolone. Time as an inpatient was recorded for only 10
patients: total durations were 14 and 5 days for ciclosporin
and 54, 48, 46, 38, 16, 7, 6 and 1 for prednisolone. Patterns
of resource use were costed using national reference values
(see Patients and methods: Resource use and cost). Although
costs for patients receiving ciclosporin were less over
24 weeks, the decrease was not statistically significant:
£1046 (95% CI: £3534 to £1341) (see Table 3).
Cost-effectiveness analysis
The joint distribution of incremental cost and outcome for the
base case analysis is shown graphically in Figure 1 (see also
Table 3). Patients allocated to ciclosporin (compared with
prednisolone) experienced a modest average increase in QoL
(0055 QALYs; 95% CI 0018–0093) over 24 weeks. Health
costs were lower for patients receiving ciclosporin but the dif-
ference was imprecise: £1160; 95% CI: 2991 to 672); cost
differences were predominantly driven by differences in hos-
pitalization (Table 2). The joint distribution of cost and out-
come is summarized within the NMB metric. Using a WTP
criterion of less than £20 000 per QALY gained, the NMB
associated with ciclosporin-initiated therapy was positive
£2263 (95% CI: 216–4311). Thus, the base case analysis
Table 1 Completeness of data by follow-up visit
Ciclosporin
(N = 59)
n (%)
Prednisolone
(N = 53)
n (%)
Total
(N = 112)
n (%)
Health status
EQ-5D baseline 56 (95) 52 (98) 108 (96)
EQ-5D 8 weeks 46 (78) 41 (77) 87 (78)
EQ-5D 24 weeks 41 (69) 29 (55) 70 (63)
Complete cases 39 (66) 28 (53) 67 (60)
Resource use
Drug use 59 (100) 53 (100) 112 (100)
Health service 8 weeks 47 (80) 38 (72) 85 (76)
Health service
24 weeks
41 (69) 34 (64) 75 (67)
Complete cases 38 (64) 29 (55) 67 (60)
Health status and resource use
Complete cases 32 (54) 23 (43) 55 (49)
EQ-5D, EuroQol five dimensions questionnaire.
© 2017 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd
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suggests NHS resources would be better directed to ciclos-
porin- than prednisolone-initiated therapy in terms of cost-
effectiveness. This finding is echoed in the cost-effectiveness
acceptability curve, which expresses the NMB finding as a
probability (Fig. 2: all patients). The likelihood that ciclos-
porin-initiated treatment is cost-effective is 985% given a
WTP criterion of less than £20 000/QALY gained (Table 3).
Sensitivity analyses
Comparing mean costs and QoL estimates using different
modelling assumptions supported the base case finding
(Table 3). The qualitative similarity of imputed and complete
case estimates supports the validity of the imputation process
and assumptions.
Subgroup analyses
There was no interaction between treatment effect and base-
line covariates except in the case of index lesion size. The 40
patients (36%) recruited with large lesions (≥ 20 cm2) experi-
enced a different pattern of costs from the patients with smal-
ler lesions (see Fig. 3 and Table 3).
Ciclosporin-initiated treatment markedly lowered costs for
patients presenting with large lesions (£5310, 95% CI
9729 to 891), but not patients with smaller lesions
(£1007, 95% CI 269 to 2283). These differences were dri-
ven by the pattern of hospitalization, which predominantly
occurred in patients receiving prednisolone and may be linked
to the occurrence of serious adverse events.12
For patients presenting with large lesions, ciclosporin-
initiated treatment appears to be a cost-effective strategy
(Figs 2 and 3: index lesion ≥ 20 cm2). However, for patients
presenting with smaller lesions, for ciclosporin-initiated treat-
ment, cost-effectiveness (£23 374/QALY) is uncertain with
the 95% confidence region including preference for either
treatment; consequently neither strategy is clearly a preferred
use of NHS resources for patients with smaller lesions (Figs 2
and 3: index lesion < 20 cm2).
Value of further research
An EVPI analysis was conducted to explore the value of reduc-
ing uncertainty about the cost-effectiveness of ciclosporin- or
prednisolone-initiated therapy. EVPI analysis at the patient
level was conducted treating the two trial strata for index
lesion size as independent trials. There is considerable cer-
tainty about the findings for the trial as a whole as well as for
patients with large lesions: the remaining value of obtaining
perfect information is low (Fig. 4). However, there remains
Table 2 Health status, resource use and cost (complete cases)
Ciclosporin (C) Prednisolone (Pr) (C)–(Pr)a
Mean (SD) Mean (SD) Mean (95% CI)
Health status
EQ-5D baseline 051 (035) 044 (038) 008 (006 to 022)
EQ-5D 8 weeks 065 (030) 053 (039) 012 (003 to 027)
EQ-5D 24 weeks 080 (022) 066 (038) 015 (001 to 030)
EQ-5D AUC 033 (008) 029 (015) 004 (002 to 010)
Resource useb
Drug use (g)c 456 (233) 85 (51)
NHS contacts (0–8 weeks)
GP clinic visits 234 (732) 111 (166) 124 (092 to 339)
GP home visits 002 (015) 021 (062) 019 (039 to 001)
Practice nurse visits 357 (854) 382 (760) 024 (368 to 319)
District nurse visits 153 (423) 242 (709) 089 (345 to 167)
Outpatient visits 455 (824) 334 (671) 121 (197 to 439)
Inpatient days 053 (230) 386 (1070) 333 (684 to 018)
NHS contacts (9–24 weeks)
GP clinic visits 066 (168) 056 (121) 010 (056 to 076)
GP home visits 000 (000) 026 (154) 026 (078 to 025)
Practice nurse visits 261 (765) 315 (828) 054 (417 to 310)
District nurse visits 273 (878) 512 (2040) 239 (975 to 498)
Outpatient visits 429 (944) 215 (345) 215 (097 to 526)
Inpatient days 000 (000) 221 (765) 221 (478 to 036)
Cost
Drug cost (0–24 weeks) 1211 (618) 222 (132) 989 (828 to 1151)
Care cost (0–8 weeks) 1151 (1869) 2344 (4816) 1193 (2814 to 429)
Care cost (9–24 weeks) 841 (1585) 1587 (3652) 746 (2066 to 574)
AUC, area under the curve; CI, confidence interval; EQ-5D, EuroQol five dimensions questionnaire; GP, general practitioner; NHS, National
Health Service. aOrdinary least squares regression-estimated means and 95% CIs. bResource use has different missing values in the two peri-
ods: overall resource use is not a simple sum of these items. cAverage (mean) weight of allocated study drug.
© 2017 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd
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considerable uncertainty about the management of smaller
lesions and the probabilistic value of removing this uncer-
tainty is significant. In 2011, 580 patients were hospitalized
in England with a primary diagnosis of PG.22 Within the trial,
64% of patients presented with smaller lesions: if generalizable
then the treatment of 370 patients a year might be affected by
greater certainty about treatment. Assuming the findings
affected care for 10 years the population affected might num-
ber 3700; taking the upper bound of £336/patient, the popu-
lation EVPI is £124 million, similar to the average cost of a
nationally recruiting multicentre clinical trial (undiscounted
costs).34 However, taking into consideration the particular dif-
ficulties of conducting trials in this patient group, there may
not be scope to conduct further definitive trial in patients with
smaller lesions, and efforts might be better placed in investi-
gating new interventions or topical treatments.
Other end-points
The three QoL measures used in the STOP GAP trial are
reported in Table 4. EQ-VAS, like EQ-5D, provides 6-month
approximations of quality-adjusted survival for each treatment
group. EQ-VAS is scored 1–100: equivalent QALY scores are
obtained by dividing by 100, although EQ-VAS is not recom-
mended for QALY estimation within trials, as values are pref-
erence-rated rather than societal. DLQI is scored 0–30: the
average score over the 6-month follow-up period is reported,
using the AUC between the three time points to calculate the
average. Being a disease-specific QoL measure, the DLQI is
potentially more sensitive to change than a generic measure.
Between-group differences for all three imputed QoL mea-
sures are shown in Table 4, including unadjusted, baseline
score-adjusted and full covariate-adjusted estimates. For each
measure, there is a trend favouring ciclosporin.
Discussion
The STOP GAP trial featured a pragmatic multicentre design
reflecting real-world clinical practice; thus, cost and outcome
profiles are likely to reflect routine care in NHS settings.
Patient-level data from the STOP GAP trial provide the most
robust evidence to date on whether ciclosporin or pred-
nisolone is cost-effective as first-line treatment for patients
with PG. The base case analysis (using multiple imputation)
found ciclosporin-initiated treatment to be cost-effective com-
pared with prednisolone, primarily due to a modest net cost
savings and improvement in QoL. However, this finding was
driven by the performance of the subgroup of patients with
large lesions. In the majority of patients with smaller lesions
(< 20 cm2) the estimated cost-effectiveness was too imprecise
to differentiate between treatments. These findings are consis-
tent with the results of the clinical trial, which found no dif-
ference between treatments in speed of healing, 6-month
healing rates or recurrence, but a (near-significant) difference
in the EQ-5D based on complete cases. Further, the trial
reported a (near-significant) difference in more seriousTa
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adverse reactions with prednisolone, particularly for infec-
tions, which might increase costs.
There are several caveats to these findings. PG is a rare dis-
ease and recruitment is problematic; although the largest trial
of its kind, STOP GAP recruited only 112 patients from 39
U.K. hospitals over 35 years. Lesion size was a stratification
variable within the trial randomization making the strata sub-
groups nested randomized controlled comparisons within the
overall trial. Reflecting the subgroup patient numbers,
differentiation of cost-effectiveness by lesion size would be
strengthened by further evidence before prioritizing ciclos-
porin routinely for patients with large lesions.
Another weakness is the incompleteness of the data con-
tributing to the economic analysis, a consequence of trying to
maintain data quality over so many sites and time, and when
the energy of trialists might focus on the clinical data. Explor-
ing the consequences of imputation, the findings appear
robust within a range of sensitivity analyses.
A final issue concerns the profile of costs and EQ-5D
scores over time (Table 2). In the case of QoL, differences
seem to be present and continuing beyond 24 weeks while
costs have not clearly converged (accepting the different
time periods involved). Thus, there might be a case to
model extrapolated costs and outcomes beyond 24 weeks.
In essence, modelling an extrapolated time horizon is
appropriate when it (i) permits better characterization of
the decision problem; (ii) allows evidence synthesis (e.g.
from multiple trials); or, (iii) improves characterization of
uncertainty.35 While the within-trial analysis presented pro-
vides findings relevant to health service decision-makers,
evidence is lacking on which to model plausible longer-
term treatment and prognosis of patients with PG. Although
the assumptions involved and quality of available trial data
further limit the value of such modelling, any attempt
would be likely to further emphasize the value of ciclos-
porin in preference to prednisolone in large lesions. The
trial also captured relapses of symptoms beyond 24 weeks:
these were infrequent and balanced between groups; thus,
their inclusion would not influence the findings.
For patients presenting with smaller lesions the economic
and clinical findings align in the sense that clinical outcomes
are similar and the cost-effectiveness analysis is too imprecise
to differentiate between these strategies. Uncertainty about the
cost-effectiveness of ciclosporin- or prednisolone-initiated
therapy for patients with small lesions is unlikely to be
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Fig 4. Expected value of perfect information:
overall and subgroup analysis (£, 2015).
QALY, quality-adjusted life year.
Table 4 EQ-5D, EQ-VAS and DLQI estimates: ciclosporin compared
with prednisolone
AUC estimates
Mean
difference 95% CI
EQ-5D imputed, unadjusted 0061 0016 to 0105
EQ-5D imputed, baseline
adjusted
0046 0010 to 0083
EQ-5D imputed, covariate
adjusted
0055 0018 to 0093
Index lesion < 20 cm2 0043 0001 to 0085
Index lesion ≥ 20 cm2 0077 0004 to 0151
EQ-VAS imputed, unadjusted 2214 0799 to 5227
EQ-VAS imputed, baseline
adjusted
2051 0501 to 4603
EQ-VAS imputed, covariate
adjusted
2556 0117 to 5229
Index lesion < 20 cm2 2862 0431 to 6155
Index lesion ≥ 20 cm2 1970 2315 to 6255
DLQI imputed, unadjusted 2646 4796 to 0497
DLQI imputed, baseline adjusted 1214 2685 to 0258
DLQI imputed, covariate adjusted 1202 2719 to 0316
Index lesion < 20 cm2 1005 2795 to 0785
Index lesion ≥ 20 cm2 1566 4350 to 1218
AUC, area under the curve; CI, confidence interval; DLQI, Der-
matology Life Quality Index; EQ-5D, EuroQol five dimensions
questionnaire; EQ-VAS, EQ visual analogue scale.
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resolved, at least within the NHS jurisdiction, given the chal-
lenges in conducting a further definitive trial, although EVPI
suggests there might be value in doing so. It is likely in the
health service setting that uncertainty about cost-effectiveness
will be a secondary concern, with the clinical findings of simi-
lar effectiveness permitting continued use of either ciclos-
porin- or prednisolone-initiated therapy as the clinical context
dictates. The subgroup analysis indicates ciclosporin may be
preferred on cost-effectiveness grounds, particularly in patients
with large lesions.
References
1 Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyo-
derma gangrenosum. BMJ 2006; 333:181–4.
2 Binus AM, Qureshi AA, Li VW et al. Pyoderma gangrenosum: a
retrospective review of patient characteristics, comorbidities and
therapy in 103 patients. Br J Dermatol 2011; 165:1244–50.
3 Su WP, Davis MD, Weenig RH et al. Pyoderma gangrenosum: clin-
icopathologic correlation and proposed diagnostic criteria. Int J Der-
matol 2004; 43:790–800.
4 Tremezaygues L, Schmaltz R, Vogt T et al. [Management of pyo-
derma gangrenosum. An update on clinical features, diagnosis and
therapy]. Hautarzt 2010; 61:345–53.
5 Zuo KJ, Fung E, Tredget EE et al. A systematic review of post-sur-
gical pyoderma gangrenosum: identification of risk factors and
proposed management strategy. J Plast Reconstr Aesthet Surg 2015;
68:295–303.
6 Langan SM, Groves RW, Card TR et al. Incidence, mortality, and
disease associations of pyoderma gangrenosum in the United
Kingdom: a retrospective cohort study. J Invest Dermatol 2012;
132:2166–70.
7 Miller J, Yentzer BA, Clark A et al. Pyoderma gangrenosum: a
review and update on new therapies. J Am Acad Dermatol 2010;
62:646–54.
8 British Association of Dermatologists. Patient information leaflet
on pyoderma gangrenosum. (London, BAD: 2010, updated
2013). Available at: http://www.bad.org.uk/for-the-public/patie
nt-information-leaflets/pyoderma-gangrenosum (last accessed 25
November 2016).
9 Reichrath J, Bens G, Bonowitz A et al. Treatment recommendations
for pyoderma gangrenosum: an evidence-based review of the liter-
ature based on more than 350 patients. J Am Acad Dermatol 2005;
53:273–83.
10 Brooklyn TN, Dunnill MG, Shetty A et al. Infliximab for the treat-
ment of pyoderma gangrenosum: a randomised, double blind, pla-
cebo controlled trial. Gut 2006; 55:505–9.
11 Craig FF, Thomas KS, Mitchell EJ et al.; UK Dermatology Clinical
Trials Network’s STOP GAP Trial Team. UK Dermatology Clinical
Trials Network’s STOP GAP trial (a multicentre trial of pred-
nisolone versus ciclosporin for pyoderma gangrenosum): protocol
for a randomised controlled trial. Trials 2012; 13:51.
12 Ormerod AD, Thomas KS, Craig FE et al. UK Dermatology Clinical
Trials Network’s STOP GAP Team. Comparison of the two most
commonly used treatments for pyoderma gangrenosum: results of
the STOP GAP randomised controlled trial. BMJ 2015; 350:h2958.
13 Drummond MF, Sculpher MJ, O’Brien B, Stoddart GL, Torrance
GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford:
Oxford University Press, 2005.
14 Kind P, Dolan P, Gudex C, Williams A. Variations in population
health status: results from a United Kingdom national question-
naire survey. BMJ 1998; 316:736–41.
15 Dolan P, Gudex C, Kind P, Williams A. A Social Tariff for EuroQol:
Results from a UK general population survey. Discussion paper 138. York,
U.K.: Centre for Health Economics, University of York, 1995.
Available at: http://www.york.ac.uk/media/che/documents/pape
rs/discussionpapers/CHE%20Discussion%20Paper%20138.pdf (last
accessed 17 April 2017).
16 Dolan P, Gudex C, Kind P, Williams A. The time trade-off
method: results from a general population survey. Health Econ
1996; 5:141–54.
17 Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a
simple practical measure for routine clinical use. Clin Exp Dermatol
1994; 19:210–6.
18 Billingham L, Abrams KR, Jones DR. Methods for the analysis of
quality-of-life and survival data in health technology assessment.
Health Technol Assess 1999; 3:1–152.
19 Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in
trial-based cost-effectiveness analysis: the importance of control-
ling for baseline utility. Health Econ 2005; 14:487–96.
20 NHS Prescription Services. Prescription Cost Analysis (PCA) Data, England
2012. Available at: http://content.digital.nhs.uk/catalogue/
PUB10610 (accessed 25 November 2016).
21 Department of Health. Reference Cost Collection: National schedule of refer-
ence costs – year 2011–12 – NHS trusts and NHS foundation trusts. Available
at: https://www.gov.uk/government/publications/nhs-reference-
costs-financial-year-2011-to-2012 (accessed 25 November 2016).
22 NHS Digital. Hospital Episode Statistics, Admitted Patient Care – England,
2011–12. Available at: http://content.digital.nhs.uk/catalogue/
PUB08288 (accessed 25 November 2016).
23 Krawzik K, Kenney A (eds). DRG Desk Reference (ICD-10-CM) 2015.
Salt Lake City, UT: Optum 360; 2015.
24 Curtis L. Unit Costs of Health and Social Care 2012. Personal Social Ser-
vices Research Unit. Canterbury, U.K.: University of Kent; 2012.
Available at: http://www.pssru.ac.uk/project-pages/unit-costs/
2012 (accessed 30 December 2016).
25 Curtis L, Burns A. Unit Costs of Health and Social Care 2016. Personal
Social Services Research Unit. Canterbury, U.K.: University of
Kent; 2016. Available at: http://www.pssru.ac.uk/project-pages/
unit-costs/2016 (accessed 30 December 2016).
26 Sterne JA, White IR, Carlin JB et al. Multiple imputation for miss-
ing data in epidemiological and clinical research: potential and pit-
falls. BMJ 2009; 338:b2393.
27 White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention
to treat analysis in randomised trials with missing outcome data.
BMJ 2011; 342:d40.
28 Faria R, Gomes M, Epstein D, White IR. A guide to handling miss-
ing data in cost-effectiveness analysis conducted within ran-
domised controlled trials. Pharmacoeconomics 2014; 32:1157–70.
29 White IR, Royston P, Wood AM. Multiple imputation using
chained equations: issues and guidance for practice. Stat Med 2011;
30:377–99.
30 Willan AR, Briggs AH, Hoch JS. Regression methods for covariate
adjustment and subgroup analysis for non-censored cost-effective-
ness data. Health Econ 2004; 13:461–75.
31 National Institute for Health and Care Excellence. Guide to the Methods
of Technology Appraisal. PMG9. London: NICE, 2013. Available at:
https://www.nice.org.uk/process/pmg9 (accessed 25 November
2016).
32 Claxton K, Sculpher M, Drummond M. A rational framework for
decision making by the National Institute for Clinical Excellence
(NICE). Lancet 2002; 360:711–5.
33 Husereau D, Drummond M, Petrou S et al. CHEERS Task Force.
Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) statement. BMJ 2013; 346:f1049.
© 2017 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd
on behalf of British Association of Dermatologists.
British Journal of Dermatology (2017)
Cost-effectiveness analysis of the STOP GAP trial, J.M. Mason et al. 9
34 Raftery J, Young A, Stanton L et al. Clinical trial metadata: defining
and extracting metadata on the design, conduct, results and costs
of 125 randomised clinical trials funded by the National Institute
for Health Research Health Technology Assessment programme.
Health Technol Assess 2015; 19:1–138.
35 Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-
based economic evaluation for health care decision making? Health
Econ 2006; 15:677–87.
© 2017 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd
on behalf of British Association of Dermatologists.
British Journal of Dermatology (2017)
10 Cost-effectiveness analysis of the STOP GAP trial, J.M. Mason et al.
